Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 May 1;174(5):459-467.
doi: 10.1176/appi.ajp.2016.16050548. Epub 2017 Jan 10.

Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine

Maria Sullivan  1 , Adam Bisaga  1 , Martina Pavlicova  1 , C Jean Choi  1 , Kaitlyn Mishlen  1 , Kenneth M Carpenter  1 , Frances R Levin  1 , Elias Dakwar  1 , John J Mariani  1 , Edward V Nunes  1
Affiliations
Randomized Controlled Trial

Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine

Maria Sullivan et al. Am J Psychiatry. .

Abstract

Objective: At present there is no established optimal approach for transitioning opioid-dependent adults to extended-release injection naltrexone (XR-naltrexone) while preventing relapse. The authors conducted a trial examining the efficacy of two methods of outpatient opioid detoxification for induction to XR-naltrexone.

Method: Participants were 150 opioid-dependent adults randomly assigned 2:1 to one of two outpatient detoxification regimens, naltrexone-assisted detoxification or buprenorphine-assisted detoxification, followed by an injection of XR-naltrexone. Naltrexone-assisted detoxification lasted 7 days and included a single day of buprenorphine followed by ascending doses of oral naltrexone along with clonidine and other adjunctive medications. Buprenorphine-assisted detoxification included a 7-day buprenorphine taper followed by a week-long delay before administration of XR-naltrexone, consistent with official prescribing information for XR-naltrexone. Participants from both groups received behavioral therapy focused on medication adherence and a second dose of XR-naltrexone.

Results: Compared with participants in the buprenorphine-assisted detoxification condition, participants assigned to naltrexone-assisted detoxification were significantly more likely to be successfully inducted to XR-naltrexone (56.1% compared with 32.7%) and to receive the second injection at week 5 (50.0% compared with 26.9%). Both models adjusted for primary type of opioid use, route of opioid administration, and morphine equivalents at baseline.

Conclusions: These results demonstrate the safety, efficacy, and tolerability of low-dose naltrexone, in conjunction with single-day buprenorphine dosing and adjunctive nonopioid medications, for initiating adults with opioid dependence to XR-naltrexone. This strategy offers a promising alternative to the high rates of attrition and relapse currently observed with agonist tapers in both inpatient and outpatient settings.

Trial registration: ClinicalTrials.gov NCT01377610.

Keywords: Buprenorphine; Detoxification; Injectable Naltrexone; Naltrexone; Opioid Dependence; Outpatient.

PubMed Disclaimer

Conflict of interest statement

Disclosures

All remaining authors report no financial relationships with commercial interests.

Figures

Figure 1
Figure 1
CONSORT diagram of participants in a controlled study of oral naltrexone vs. buprenorphine as detoxification strategies for induction onto extended-release naltrexone in opioid-dependent adults
Figure 2
Figure 2
Longitudinal observed daily proportion of participants with at least mild withdrawal on average (mean Clinical Opiate Withdrawal Scale ≥ 5), by treatment arm (Figure 2A); longitudinal observed daily proportion of participants with at least one report of moderate-severe withdrawal (maximum Clinical Opiate Withdrawal Scale ≥ 12) by treatment arm (Figure 2B).
Figure 3
Figure 3
Longitudinal Clinical Opiate Withdrawal Scale (Figure 3A) and Hamilton Depression Rating Scale (Figure 3B) scores during weeks after XR-naltrexone induction, by treatment arm.a aError bars indicate standard deviation.
See this image and copyright information in PMC

Comment in

  • Current Progress in Opioid Treatment.
    Woody GE. Woody GE. Am J Psychiatry. 2017 May 1;174(5):414-416. doi: 10.1176/appi.ajp.2016.16121398. Am J Psychiatry. 2017. PMID: 28457152 No abstract available.

References

    1. Center for Behavioral Health Statistics and Quality. (HHS Publication No. SMA 15-4927, NSDUH Series H-50).Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. 2015 Retrieved from http://www.samhsa.gov/data/. Accessed on April 24, 2016.
    1. Centers for Disease Control and Prevention (CDC) CDC – Prescription Painkiller Overdoses Policy Impact Brief – Home and Recreational Safety. 2013
    1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in Drug and Opioid Overdose Deaths – United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 64(50–51):1378–82. - PubMed
    1. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled multicentre randomised trial. Lancet. 2011;377(9776):1506–13. - PubMed
    1. Physicians Desk Reference. 2015 http://www.pdr.net/drug-summary/vivitrol?druglabelid=1199&id=2886.

Publication types

MeSH terms

Associated data